| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.01 M USD | -3.64 M USD | 25.89 M USD | -33.10 M USD | -83.75 M USD | -55.05 M USD | -43.61 M USD | -28.55 M USD | -19.94 M USD | -18.47 M USD | -19.12 M USD | -34.48 M USD |
| Depreciation & Amortization | 2.48 M USD | 1.55 M USD | 1.07 M USD | 230000 USD | 290000 USD | 138000 USD | 146000 USD | 149000 USD | 173000 USD | 389000 USD | 470000 USD | 351000 USD |
| Stock-Based Compensation | 7.16 M USD | 831000 USD | 7.28 M USD | 1.34 M USD | 3.40 M USD | 3.63 M USD | 3.20 M USD | 2.61 M USD | 863000 USD | 635000 USD | 326000 USD | 3.47 M USD |
| Capital Expenditures | 1.19 M USD | 2.31 M USD | 8.52 M USD | 4.99 M USD | 839000 USD | — | 64000 USD | 376000 USD | 23000 USD | 468000 USD | 272000 USD | 4000 USD |
| Cash Flow from Investing | -474000 USD | -19.88 M USD | -19.76 M USD | 55.43 M USD | 48.19 M USD | 9.66 M USD | 27.39 M USD | -71.32 M USD | -11.20 M USD | -1.31 M USD | 37.36 M USD | 33.86 M USD |
| Cash Flow from Financing | 24.38 M USD | 2.10 M USD | 2.50 M USD | -45.01 M USD | 49.55 M USD | 60.38 M USD | 327000 USD | 111.33 M USD | 21.08 M USD | 948000 USD | 9.31 M USD | 2.57 M USD |
| Dividends Paid | — | — | — | 45.03 M USD | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | 82000 USD | — |
| Free Cash Flow | -180000 USD | -5.96 M USD | 17.38 M USD | -38.08 M USD | -84.59 M USD | — | -43.68 M USD | -28.93 M USD | -19.96 M USD | -18.94 M USD | -19.39 M USD | -34.49 M USD |
Gyre Therapeutics Inc. is a biotechnology firm dedicated to the discovery and development of innovative therapies for unmet medical needs. Its primary function is to leverage cutting-edge research and development technologies to address complex diseases and conditions that currently lack effective treatments. Gyre Therapeutics operates within the healthcare and biomedical sectors, impacting areas such as oncology, neurology, and rare genetic disorders. The company employs a robust pipeline strategy, focusing on both in-house R&D and collaborative partnerships to accelerate drug development and facilitate clinical trials. Through strategic alliances with academic institutions and pharmaceutical companies, Gyre Therapeutics aims to enhance its scientific capabilities and expand its therapeutic portfolio. As a specialized entity in the biotech industry, Gyre Therapeutics plays a crucial role in advancing medical science, potentially transforming patient care by bringing novel bio-pharmaceutical products to the market.